Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

BACKGROUND: New therapeutic principles in clinical oncology require the adjustment of response criteria to govern therapy decisions. For advanced hepatocellular carcinoma (HCC) a new era has recently begun by the approval of the multikinase inhibitor sorafenib. As a unique feature, HCC usually devel...

Descripción completa

Detalles Bibliográficos
Autores principales: Horger, Marius, Lauer, Ulrich M, Schraml, Christina, Berg, Christoph P, Koppenhöfer, Ursula, Claussen, Claus D, Gregor, Michael, Bitzer, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714320/
https://www.ncbi.nlm.nih.gov/pubmed/19558720
http://dx.doi.org/10.1186/1471-2407-9-208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714320/
https://www.ncbi.nlm.nih.gov/pubmed/19558720
http://dx.doi.org/10.1186/1471-2407-9-208

Ejemplares similares